
NovaBridge Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on the stock and has
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| NBP | NovaBridge Biosciences | 0.83 | -3.40 | -80.38% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.83 | -80.38% |

NovaBridge Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on the stock and has

The latest update is out from NovaBridge Biosciences ( ($NBP) ). NovaBridge Biosciences announced on October 28, 2026, that Charles “Chuck” Silberstein, M.D., M.B.A., CFA will become Chief Financial Officer

NovaBridge (NBP) announced the appointment of Chuck Silberstein as CFO, effective November 2. Silberstein succeeds Kyler Lei, who is stepping down following a successful tenure with the company. Most recently,

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on NovaBridge Biosciences today and set a price target of $9.00. Andres Y. Maldonado has given his Buy rating due

NovaBridge Biosciences ( ($NBP) ) has provided an announcement. NovaBridge Biosciences reported mature Phase 1b data for its lead candidate givastomig on October 25, 2026, presenting the results at the

NovaBridge (NBP) Biosciences announced the presentation of updated results from the ongoing Phase 1b study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with nivolumab and chemotherapy for

NovaBridge Biosciences ( ($NBP) ) has issued an update. On October 23, 2026, NovaBridge Biosciences reported that clinical data from its ongoing Phase 1 trial of ragistomig, also known as

NovaBridge Biosciences ( ($NBP) ) has issued an update. On October 13, 2026, Visara, NovaBridge’s majority-owned ophthalmology subsidiary, signed an exclusive license agreement with Wuhan Hiteck Biological Pharma for worldwide

Wuhan Hiteck Biological Pharma Co. announced that it has entered into an exclusive license agreement with Visara, a majority-owned ophthalmology subsidiary of NovaBridge (NBP) Biosciences, for HT006.2.2, an investigational next-generation

The latest announcement is out from NovaBridge Biosciences ( ($NBP) ). NovaBridge Biosciences reported on September 8, 2026, that it has appointed veteran healthcare executive Martin Dewhurst as an independent
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 31, 2027TBA | $102.06M | $-0.19 | $0.00 | 0.10 | -1.88 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.